adamantane has been researched along with metformin in 223 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 30 (13.45) | 29.6817 |
| 2010's | 180 (80.72) | 24.3611 |
| 2020's | 13 (5.83) | 2.80 |
| Authors | Studies |
|---|---|
| Ahrén, B; Gomis, R; Mills, D; Schweizer, A; Standl, E | 1 |
| Ahrén, B; Foley, JE; Pacini, G; Schweizer, A | 1 |
| Bosi, E; Camisasca, RP; Collober, C; Garber, AJ; Rochotte, E | 1 |
| Couturier, A; Dejager, S; Foley, JE; Schweizer, A | 1 |
| Ahrén, B; Foley, JE; Pacini, G; Schweizer, A; Tura, A | 1 |
| Bolli, G; Cohen, SE; Dotta, F; Rochotte, E | 1 |
| Ahrén, B | 3 |
| Cefalu, WT; Urquhart, S | 1 |
| Campestrini, J; Flannery, B; He, YL; Jarugula, V; Leon, S; Ligueros-Saylan, M; Zinny, MA | 1 |
| Campestrini, J; He, YL; Jarugula, V; Leon, S; Ligueros-Saylan, M; Paladini, S; Sabia, H; Zhang, Y | 1 |
| Calle Pascual, A; Dejager, S; Foley, J; Göke, B; Hershon, K; Kerr, D; Schweizer, A; Shao, Q | 1 |
| Dejager, S; Foley, J; Halimi, S; Minic, B; Schweizer, A | 1 |
| Ahrén, B; Byiers, S; Dejager, S; Ferrannini, E; Fonseca, V; Matthews, D; Shao, Q; Zinman, B | 1 |
| Goodman, M; Penman, J; Thurston, H | 1 |
| Barnett, AH; Piya, MK; Tahrani, AA | 1 |
| Bosi, E; Dotta, F; Goodman, M; Jia, Y | 1 |
| Dole, WP; He, YL; Herron, J; Ligueros-Saylan, M; Picard, F; Sabo, R; Wang, Y | 1 |
| Scherbaum, WA | 1 |
| Mathieu, C | 1 |
| Barnett, AH | 1 |
| Paquot, N; Scheen, AJ | 1 |
| Bosi, E; Dejager, S; Schweizer, A | 1 |
| Chen, RS; DeFronzo, RA; Garber, AJ; Hissa, MN; Luiz Gross, J; Ravichandran, S; Yuyan Duan, R | 1 |
| Bolli, G; Colin, L; Dotta, F; Goodman, M; Minic, B | 1 |
| Allen, E; Chen, R; Jadzinsky, M; Paz-Pacheco, E; Pfützner, A; Xu, Z | 1 |
| Banerji, MA; Baron, M; Blonde, L; Braceras, R; Dagogo-Jack, S; Marcellari, A; Pratley, RE; Purkayastha, D | 1 |
| Bravis, V; Devendra, D; Gohel, B; Hassanein, M; Hui, E; Mehar, S; Salih, S | 1 |
| Ahrén, B; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, VA; Matthews, DR; Zinman, B | 1 |
| LaSalle, JR | 1 |
| Filozof, C; Gautier, JF | 1 |
| Ahren, B; Couturier, A; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, V; Matthews, DR; Zinman, B | 1 |
| Banerji, MA; Francis, BH; Purkayastha, D | 1 |
| Berglind, N; Chen, R; Neutel, J; Ravichandran, S; Raz, I; Stenlöf, K | 1 |
| Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 5 |
| Charpentier, G; Gause-Nilsson, I; Hellqvist, A; Ostgren, CJ; Scheen, AJ | 1 |
| Eriksson, J; Gallwitz, B; Gause-Nilsson, I; Göke, B; Hellqvist, A | 1 |
| Ahrén, B; Bosi, E; Foley, JE | 1 |
| Boulton, DW; Brenner, E; Handschuh del Corral, M; Komoroski, B; Kornhauser, D; Li, L; Patel, CG; Vachharajani, N | 1 |
| Allen, E; Chen, R; Frederich, R; Paz-Pacheco, E; Pfützner, A | 1 |
| Andrews, C; Barnett, A; Geransar, P; Hanif, W; Hassanein, M; Kamal, A; Lister, N; Malik, W | 1 |
| Allen, E; Chen, R; Donovan, M; Fleming, D; Karyekar, C; Ravichandran, S | 1 |
| Albuquerque, JL; Alves, Gdos S; Canadas, V; Cunha, RA; Ferreira, VM; Gusmão, A; Ibiapina, GR; Lima, JG; Montenegro, L; Nóbrega, LH; Pontes, L; Pontes, S; Vilar, L | 1 |
| Netea, MG; Smits, P; Tack, CJ; van Poppel, PC | 1 |
| Boulton, DW; Huang, J; LaCreta, FP; Li, L; Smith, CH; Tang, A | 1 |
| Gause-Nilsson, I; Pan, CY; Tou, C; Yang, W; Zhao, J | 1 |
| Barboza, J; Sando, KR; Taylor, J; Willis, C | 1 |
| Jermendy, G | 2 |
| Bergenheim, K; Granström, O; Henriksson, M; McEwan, P; Sennfält, K | 1 |
| Czupryniak, L; Grzeszczak, W; Kolasa, K; Lomon, ID; McEwan, P; Sciborski, C | 1 |
| Scheen, AJ | 3 |
| Fonseca, V; Hirshberg, B; Karyekar, C; Zhu, T | 1 |
| Bergenheim, K; Duprat-Lomon, I; Erhardt, W; McEwan, P | 1 |
| Barnett, AH; Charbonnel, B; Chen, R; Donovan, M; Fleming, D | 1 |
| Derosa, G; Maffioli, P | 2 |
| Bader, G; Han, P; Liu, J; Lu, J; Lv, X; Ma, J; Pan, C; Xing, X; Zheng, S | 1 |
| Alexander, CM; Berger, JP; Carr, RD; Katzeff, HL; Thornberry, N; Xu, SS | 1 |
| Dotta, F; Fondelli, C; Guarino, E; Nigi, L; Patti, A | 1 |
| Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Maffioli, P; Ragonesi, PD; Romano, D | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H | 1 |
| Fisman, EZ; Goldenberg, I; Klempfner, R; Leor, J; Tenenbaum, A | 1 |
| Barbieri, M; Marfella, R; Paolisso, G; Rizzo, MR | 1 |
| Frier, BM; Inkster, B; Zammitt, NN | 1 |
| Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D | 1 |
| Colette, C; Dejager, S; Guerci, B; Huet, D; Monnier, L; Petit, C; Quéré, S; Raccah, D; Serusclat, P; Valensi, P | 1 |
| Charbonnel, B; Delibasi, T; Farmer, I; Hermans, MP; Jörgens, S; Lohm, L; Maheux, P; Malvolti, E; Piatti, P | 1 |
| Foley, J; Gallwitz, B; Kothny, W; Kozlovski, P; Lukashevich, V; Shao, Q | 1 |
| Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Ragonesi, PD | 2 |
| Bakris, GL; Flynn, C | 1 |
| Berndt-Zipfel, C; Dworak, M; Forst, T; Klamp, I; Löffler, A; Mitry, M; Pfützner, A | 1 |
| Genovese, S; Tedeschi, D | 1 |
| Bader, G; Geransar, P; Schweizer, A | 1 |
| Boulton, DW; Chang, M; Frevert, EU; Hsiang, BC; Keung, CF; Lacreta, FP; Li, L; Quamina-Edghill, D; Tang, A; Upreti, VV | 1 |
| Berndt-Zipfel, C; Dworak, M; Forst, T; Löffler, A; Michelson, G; Mitry, M; Pfützner, A | 1 |
| Allen, E; Fleming, D; Frederich, R; Karyekar, CS; Ravichandran, S | 1 |
| Eriksson, JG; Gallwitz, B; Gause-Nilsson, I; Göke, B; Hellqvist, Å | 1 |
| Andrews, C; Azam, M; Barnett, AH; Geransar, P; Hanif, W; Hassanein, M; Kamal, A; Malik, W | 1 |
| Hoellinger, MJ; Kothny, W; Lukashevich, V; Paldánius, PM; Strain, WD | 1 |
| Allen, E; Bryzinski, B; Cook, W; Frederich, R; Slater, J | 1 |
| Forst, T; Foteinos, G; He, YL; Kulmatycki, K; Mattapalli, D; Neelakantham, S; Taylor, A | 1 |
| Frederich, R; Karyekar, CS; Ravichandran, S | 1 |
| Aguilar-Salinas, C; Berglind, N; Fleming, D; Gross, JL; Hissa, M; Ravichandran, S; Rosenstock, J | 1 |
| Aydogdu, A; Bozoglu, E; Doruk, H; Naharci, MI; Safer, U; Tasci, I; Yilmaz, BF; Yilmaz, G | 1 |
| Chatterjee, S | 1 |
| Barnett, AH; Charbonnel, B; Donovan, M; Fleming, D; Iqbal, N; Li, J | 1 |
| Ji, LN; Li, H; Li, Q; Li, QF; Lu, JM; Pan, CY; Peng, YD; Tian, HM; Wang, L; Wang, XL; Yao, C; Zhang, RY; Zhao, ZG | 1 |
| Pradeepkumar, M; Rao, VJ; Satheeshkumar, N; Shanthikumar, S | 1 |
| Aleksandrov, AA; Chernova, TO; Dedov, II; Il'in, AV; Shestakova, MV; Shmushkovich, IA; Suhareva, OIu | 1 |
| Araga, M; Del Prato, S; Kothny, W; Lukashevich, V | 1 |
| Brook, D; Fisher, SA; Kalra, S; Montanaro, M; Monyak, J; Moses, RG; Sockler, J; Visvanathan, J | 1 |
| Bader, G; Dworak, M; Göke, R; Gruenberger, JB | 1 |
| Brada, M; Dohnalová, L; Edelsberger, T; Gerle, J; Haluzík, M; Houdová, J; Veselá, V | 1 |
| Minervini, G; Mintz, ML | 1 |
| Breitschaft, A; Darstein, C; Golor, G; Hermosillo Reséndiz, K; Hu, K | 1 |
| Aravind, SR | 1 |
| Abdel-Aziz, O; Abdel-Ghany, MF; Ayad, MF; Tadros, MM | 1 |
| Abdul-Ghani, M; Cakirca, M; Camli, AA; Cikrikcioglu, MA; Erkoc, R; Hursitoglu, M; Kanat, M; Karatoprak, C; Kiskac, M; Soysal, P; Zorlu, M | 1 |
| Keating, GM | 1 |
| Ahrén, B; Bader, G; Foley, JE; Mathieu, C; Schweizer, A | 1 |
| Calado, F; Carvalho, D; Gruenberger, JB; Johal, S; Ong, SH; Silva-Nunes, J; Viana, R; Viriato, D | 1 |
| Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D | 2 |
| Bramlage, P; Forst, T | 1 |
| Ding, M; Li, CJ; Liu, XJ; Yu, DM; Yu, P; Yu, Q; Zhang, QM | 1 |
| Del Prato, S; Foley, JE; Kothny, W; Kozlovski, P; Matthews, DR; Paldánius, PM; Stumvoll, M | 1 |
| Hirshberg, B; Iqbal, N; Lu, J; Sjöstrand, M | 1 |
| Navarro-Artieda, R; Sicras-Mainar, A | 1 |
| Choi, SA; Jang, JY; Jung, HS; Kim, HC; Kim, JH; Kim, MJ; Kim, SW; Lee, HM; Lee, KB; Ohn, JH; Park, KS; Yoon, JW | 1 |
| de Francisco, TM; Gasparetto, JC; Gimenez, AC; Pontarolo, R; Pontes, FL; Ribeiro, RP | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, S; Chinda, K; Palee, S | 1 |
| Gillen, M; Gummesson, A; Hirshberg, B; Li, H; Niazi, M; Xu, J | 1 |
| Marchesini, G; Melchiorri, D; Montilla, S; Pani, L; Sammarco, A; Siviero, PD; Tomino, C; Trotta, MP | 1 |
| Cook, W; Hansen, L; Hirshberg, B; Iqbal, N; Li, Y; Rosenstock, J; Zee, P | 1 |
| Bryzinski, B; Cook, W; Hirshberg, B; Minervini, G | 1 |
| Basiak, M; Drożdż, M; Okopień, B; Stęposz, A; Strózik, A | 1 |
| Abou Jaoude, E; Al-Arouj, M; DiTommaso, S; Fawwad, A; Latif, ZA; Orabi, A; Rosales, R; Shah, P; Vaz, J | 1 |
| Al-Mrabeh, A; Foley, JE; Hollingsworth, KG; Macauley, M; Schweizer, A; Smith, FE; Taylor, R; Thelwall, PE | 1 |
| Akin, F; Ar, IB; Ayvaz, G; Dokmetas, HS; Keskin, L; Tasan, E; Uren, E | 1 |
| Abdul-Ghani, M | 1 |
| Durán-Garcia, S; Hanefeld, M; Hardy, E; Langslet, G; Malvolti, E; Niskanen, L; Östgren, CJ; Schernthaner, G | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Inthachai, T; Kumfu, S; Lekawanvijit, S; Pongkan, W | 1 |
| Chen, YM; Lin, S; Lu, HY; Mu, PW; Shu, J; Wang, MM; Xie, RY; Zeng, LY; Zhang, YJ | 1 |
| Kothny, W; Li, L; Lukashevich, V; Lv, X; Ma, J; Ning, G; Wang, W; Woloschak, M; Yang, M | 1 |
| Deng, J; Dong, H; Gu, S; Mu, Y; Shi, L | 1 |
| Choi, SH; Hong, AR; Hwangbo, Y; Jang, HC; Kim, KM; Ku, EJ; Lee, J; Lim, S; Moon, JH | 1 |
| Asahara, S; Bartolome, A; Inoue, H; Kanno, A; Kawamoto, T; Kido, Y; Koyanagi-Kimura, M; Matsuda, T; Matsuura, Y; Mieda, Y; Ogawa, W; Seino, S; Shimizu, S; Suzuki, E; Takahashi, H; Takai, T; Yokoi, N | 1 |
| Federici, M; Kappel, BA; Marx, N | 1 |
| Chen, H; Cook, W; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Li, D; Mathieu, C; Ranetti, AE | 1 |
| Fan, X; Fan, Y; Li, X; Ren, F; Ren, G; Shen, C; Shen, J; Song, Y; Yang, J; Zhang, N; Zhang, Y; Zheng, H | 1 |
| Catrinoiu, D; Celiński, A; Chen, H; Cook, W; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Matthaei, S | 1 |
| D'Angelo, A; Derosa, G; Franzetti, I; Maffioli, P; Querci, F | 1 |
| Gu, W; Li, Y; Liang, L; Ning, G; Piao, C; Tan, X; Tian, J; Wang, S; Wang, W; Wang, Y; Wu, Y; Xin, X; Yang, G; Yin, J | 1 |
| Athanasiadou, E; Bekiari, E; Boura, P; Karagiannis, T; Liakos, A; Mainou, M; Papatheodorou, K; Rika, M; Rizava, C; Tsapas, A | 1 |
| Borg, M; Bound, MJ; Deacon, CF; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Wu, T; Zhang, X | 1 |
| Chitnis, SD; He, YL; Kulmatycki, K; Mita, S; Salunke, A; Suzuki, H; Zhou, W | 1 |
| Jing, W; Shunyou, D; Xiaochun, H; Xiaoyan, C; Yingyu, F; Yuyu, T | 1 |
| Geissel, W | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Inthachai, T; Lekawanvijit, S | 1 |
| Chitnis, SD; Han, Y; Kulmatycki, K; Mita, S; Sunkara, G; Yamaguchi, M; Zhao, R | 1 |
| Amblee, A; Fogelfeld, L; Lious, D | 1 |
| Bugáňová, M; Haluzík, M; Holubová, M; Kaválková, P; Kuneš, J; Kuzma, M; Maletínská, L; Pelantová, H; Šedivá, B; Sýkora, D; Železná, B; Zemenová, J | 1 |
| Baranov, O; Deacon, CF; Holst, JJ; Kahle, M; Nauck, MA | 1 |
| Charbonnel, B; Dejager, S; Fiquet, B; Gautier, JF; Monguillon, P; Valensi, P; Verier-Mine, O | 1 |
| Abiru, N; Ando, T; Horie, I; Kawakami, A; Shigeno, R | 1 |
| Chattipakorn, N; Chattipakorn, SC; Pongkan, W; Pratchayasakul, W; Sa-Nguanmoo, P; Sivasinprasasn, S | 1 |
| Bader, G; Brath, H; Kolaczynski, WM; Nilsson, PM; Paldánius, PM | 1 |
| Chen, H; Garcia-Sanchez, R; González González, JG; Hansen, L; Herrera Marmolejo, M; Iqbal, N; Johnsson, E; Mathieu, C | 1 |
| Aggarwal, N; Chen, H; Chin, A; Garcia-Hernandez, P; Hansen, L; Iqbal, N; Johnsson, E; Matthaei, S | 1 |
| Ji, LN; Li, H; Li, Q; Li, QF; Lu, JM; Pan, CY; Peng, YD; Tian, HM; Wang, BH; Wang, L; Yao, C; Zhao, ZG; Zhu, DL | 1 |
| Ersoy-Evans, S; Gököz, O; Gönül, M; Keseroglu, HO; Taş-Aygar, G | 1 |
| Sanyal, M; Shah, JV; Shah, PA; Shrivastav, PS | 1 |
| Al-Arouj, M; Hassoun, AA; Ibrahim, M | 1 |
| Cook, W; Hirshberg, B; Ohman, P; Perl, S; Wei, C | 1 |
| Carlsson, B; Chen, H; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Johnsson, E | 1 |
| Dong, H; Gu, S; Hu, X; Yu, D; Zeng, Y | 1 |
| Fonseca, M; Kothny, W; Kozlovski, P; Lukashevich, V; Mohan, V; Odawara, M; Paldánius, PM | 1 |
| Elkind-Hirsch, KE; Gutowski, HC; Paterson, MS; Seidemann, EL | 1 |
| Bound, MJ; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Sun, Z; Trahair, LG; Wu, H; Wu, T; Zhang, X | 1 |
| Bian, F; Du, J; Fang, H; Li, W; Liang, L; Mu, Y; Shen, L; Wang, X; Xu, C; Xu, F | 2 |
| Rakha, S; Shelbaya, S | 1 |
| Lingvay, I | 1 |
| Acurcio, FA; De Oliveira, GL; Godman, B; Guerra Júnior, AA | 1 |
| Chen, J; Leng, F; Li, F; Ling, Y; Lu, Z | 1 |
| Chodick, G; Davis, C; Melzer Cohen, C; Shalev, V | 1 |
| Hemmingsen, B; Metzendorf, MI; Richter, B; Sonne, DP | 1 |
| Eskenazi, D; Fisman, EZ; Goldenberg, I; Goldkorn, R; Klempfner, R; Leor, J; Naftali-Shani, N; Tenenbaum, A; Younis, A | 1 |
| Chen, Q; Huang, L; Kong, L; Wang, J; Wang, Z; Xu, D; Zhang, T; Zhou, X | 1 |
| Hua, WC; Li, CM; Liu, Q; Wang, H; Wang, LG | 1 |
| Aass, HCD; Åkra, S; Arnesen, H; Byrkjeland, R; Njerve, IU; Seljeflot, I; Solheim, S; Weiss, TW; Øvstebø, R | 1 |
| Bombelli, M; Dell'Oro, R; Gamba, P; Grassi, G; Maloberti, A; Mancia, G; Nicoli, F; Villa, P | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N | 1 |
| Hur, KY; Jin, SM; Kim, G; Kim, JH; Lee, MK; Oh, S | 1 |
| Chmelik, M; Harreiter, J; Kautzky-Willer, A; Kosi-Trebotic, L; Thomas, A; Trattnig, S | 1 |
| Attia, A; El-Shenawy, S; Gomaa, N; Hassan, A; Hegazy, R; Kenawy, S; Zaki, H | 1 |
| Coppenrath, VA; Hydery, T | 1 |
| Dou, J; Johnsson, E; Liu, J; Ma, J; Pan, C; Wang, C; Yao, H; Zhao, J | 1 |
| Aoki, S; Atsumi, T; Furumoto, T; Inoue, A; Kitao, N; Kurihara, Y; Manda, N; Miya, A; Miyoshi, H; Nakamura, A; Nomoto, H; Ono, K; Tsuchida, K; Yamamoto, C | 1 |
| Cho, H; Kim, JH; Lee, BW; Lee, WJ; Song, SO; Suh, S | 1 |
| Azuma, K; Goto, H; Ikeda, F; Kanazawa, A; Komiya, K; Masuyama, A; Mita, T; Ogihara, T; Ohmura, C; Osonoi, T; Osonoi, Y; Saito, M; Sato, J; Shimizu, T; Someya, Y; Suzuki, L; Takayanagi, N; Takeno, K; Uzawa, H; Watada, H | 1 |
| Chen, Y; Guo, L; Ji, L; Johnsson, E; Li, Q; Li, Y; Liu, X; Lv, X; Ma, J; Shi, Y; Wang, C; Wang, M; Zhao, J | 1 |
| Bowman, B; Cobretti, MR; Grabarczyk, T; Potter, E | 1 |
| Chen, H; Del Prato, S; Garcia-Sanchez, R; Hansen, L; Iqbal, N; Johnsson, E; Mathieu, C; Rosenstock, J | 1 |
| Liu, W; Tao, T; Wang, Y; Wu, P | 1 |
| Aa, J; Chang, Q; Gu, S; Peng, Y; Sun, J; Wang, G; Yang, N; Yin, L; Zhou, Y | 1 |
| Faria-Neto, JR; Lacerda, CS; Marino, EC; Pechmann, LM; Polesel, MG; Vianna, AGD | 1 |
| Ahmadi, N; Amdur, RL; Domingues, CC; Dore, FJ; Houston, S; Khiyami, A; Kropotova, Y; Kundu, N; Mammadova, A; Rouphael, C; Sen, S; Witkin, L | 1 |
| Chen, K; Mei, Q; Wang, J; Zhuo, T | 1 |
| Csomós, K; Cypryk, K; Dronamraju, N; Garcia-Sanchez, R; Jacob, S; Johnsson, E; Kellerer, M; Kurlyandskaya, R; Müller-Wieland, D; Rohwedder, K; Seufert, J; Sjöström, CD; Skripova, D | 1 |
| Cho, HC; Kim, NH; Kim, SG; Kwak, SH; Lee, J; Lee, YH; Lim, S; Moon, JS; Moon, MK | 1 |
| Chen, H; Garcia-Sanchez, R; Mathieu, C; Rosenstock, J; Saraiva, GL | 1 |
| Del Prato, S; Garcia-Sanchez, R; Handelsman, Y; Iqbal, N; Johnsson, E; Kurlyandskaya, R; Mathieu, C; Rosenstock, J | 1 |
| Bi, Y; Cheng, J; Gu, T; Li, D; Ma, J; Shao, J; Shi, B; Sun, Z; Xu, L; Zhang, H; Zhang, Q; Zhong, S; Zhu, D; Zhu, L | 1 |
| García-Sánchez, R; Jacob, S; Johnsson, E; Perl, S; Rosenstock, J | 1 |
| Boulton, DW; Dayton, B; Engman, H; Tang, W; Zhu, Y | 1 |
| Kaundal, PK; Mokta, JK; Mokta, K; Sahai, AK | 1 |
| Bhutani, R; Bodla, RB; Kant, R; Kapoor, G | 1 |
| Dronamraju, N; Ekholm, E; Garcia-Sanchez, R; Jabbour, SA; Johnsson, E; Lind, M; Vilsbøll, T | 1 |
| Dronamraju, N; Frias, JP; Garcia-Sanchez, R; Gonzalez-Galvez, G; Johnsson, E; Maaske, J; Peters, AL; Simonson, DC; Testa, MA | 1 |
| Dronamraju, N; Garcia-Sanchez, R; Hockings, PD; Johansson, L; Johnsson, E; Maaske, J; Wilding, JPH | 1 |
| Kaneko, Y; Nishimura, T; Oda, K; Shibata, M; Toyoshima, J | 1 |
| Deng, X; Hu, S; Li, Z; Ma, Y; Wang, Y | 1 |
| Li, M; Song, J; Ying, M; Zhuang, Y | 1 |
| Abdel-Aal, M; Abdel-Ghany, RH; Alsemeh, AE; Ghareib, SA; Sabry, D; Wahba, NS | 1 |
| Cai, ZJ; Chen, T; Li, N; Lin, WQ; Liu, MB; Zheng, B | 1 |
| Gezawa, ID; Salawu, OA; Uloko, AE; Uloko, AT | 1 |
| Frías, JP; Hockings, PD; Iqbal, N; Johansson, L; Maaske, J; Suchower, L; Wilding, JPH | 1 |
| Alegete, P; Boodida, S; Vankalapati, KR | 1 |
| Chepulis, L; Keenan, R; Lawrenson, R; Mayo, C; Paul, R | 1 |
33 review(s) available for adamantane and metformin
| Article | Year |
|---|---|
DPP-4 inhibitors.
Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin | 2007 |
Clinical management strategies for type 2 diabetes.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin-Secreting Cells; Metformin; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Combinations; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Metformin; Nitriles; Pyrrolidines; Tablets; Treatment Outcome; Vildagliptin | 2008 |
Drug evaluation: vildagliptin-metformin single-tablet combination.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Lipids; Metformin; Nitriles; Practice Guidelines as Topic; Pyrrolidines; Safety; Treatment Outcome; Vildagliptin | 2009 |
The scientific evidence: vildagliptin and the benefits of islet enhancement.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Evidence-Based Medicine; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Islets of Langerhans; Metformin; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
Translating science into clinical practice: focus on vildagliptin in combination with metformin.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Thiazolidinediones; Vildagliptin | 2009 |
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Metformin; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sensitivity and Specificity; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin | 2009 |
Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs.
Topics: Adamantane; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Metformin; Sulfonylurea Compounds | 2010 |
Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.
Topics: Adamantane; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2011 |
Saxagliptin/metformin (kombiglyze XR) for type 2 diabetes.
Topics: Adamantane; Animals; Clinical Trials as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptides; Drug Combinations; Humans; Hypoglycemic Agents; Metformin | 2011 |
Recent diabetes issues affecting the primary care clinician.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Primary Health Care; Rosiglitazone; Thiazolidinediones; Vitamin B 12 Deficiency | 2011 |
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Metformin; Nitriles; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Tablets; Treatment Outcome; Triazoles; Vildagliptin | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
Metformin + saxagliptin for type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin | 2012 |
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain | 2012 |
Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.
Topics: Adamantane; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Kidney; Metformin; Patient Selection; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Purines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Vildagliptin | 2012 |
Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Topics: Adamantane; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Metformin; Nitriles; Pyrrolidines; Tablets; Treatment Outcome; Vildagliptin | 2012 |
Drug-induced hypoglycaemia in type 2 diabetes.
Topics: Adamantane; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Peptides; Pharmacogenetics; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Venoms | 2012 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin.
Topics: Adamantane; Area Under Curve; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Treatment Outcome | 2013 |
Vildagliptin: a review of its use in type 2 diabetes mellitus.
Topics: Adamantane; Administration, Oral; Aged; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Vildagliptin | 2014 |
Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Insulin; Metformin; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2014 |
Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials.
Topics: Adamantane; Administration, Oral; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Risk Factors; Sitagliptin Phosphate; Thiazolidinediones | 2015 |
Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Nitriles; Pancreatitis; Pyrrolidines; Treatment Outcome; Vildagliptin | 2016 |
Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China.
Topics: Adamantane; Asian People; Cardiovascular Diseases; China; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Male; Metformin; Models, Economic; Quality of Life | 2016 |
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Piperidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uracil | 2017 |
Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications.
Topics: Adamantane; Brazil; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Models, Economic; Nitriles; Pyrrolidines; Vildagliptin | 2017 |
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Nitriles; Peptides; Pyrrolidines; Randomized Controlled Trials as Topic; Risk Factors; Venoms; Vildagliptin | 2017 |
A network meta-analysis for efficacy and safety of seven regimens in the treatment of type II diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Treatment Outcome; Vildagliptin | 2017 |
Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Combinations; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Tablets | 2018 |
Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
123 trial(s) available for adamantane and metformin
| Article | Year |
|---|---|
Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Double-Blind Method; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Placebos; Protease Inhibitors; Pyrrolidines | 2004 |
Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.
Topics: Adamantane; Area Under Curve; Blood Glucose; Body Mass Index; C-Peptide; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Metformin; Middle Aged; Nitriles; Placebos; Protease Inhibitors; Pyrrolidines; Vildagliptin | 2005 |
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes.
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; United Kingdom; Vildagliptin | 2007 |
Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Topics: Adamantane; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Proinsulin; Pyrrolidines; Treatment Outcome; Vildagliptin | 2007 |
Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Treatment Outcome; Vildagliptin | 2008 |
Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers.
Topics: Adamantane; Adolescent; Adult; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Female; Food-Drug Interactions; Humans; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2008 |
Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects.
Topics: Adamantane; Adolescent; Adult; Area Under Curve; Chromatography, Liquid; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Tablets; Tandem Mass Spectrometry; Therapeutic Equivalency; Vildagliptin | 2008 |
Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin.
Topics: Adamantane; Adult; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2008 |
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Time Factors; Vildagliptin | 2009 |
Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Topics: Adamantane; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Young Adult | 2009 |
Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
Topics: Adamantane; Adult; Aged; Americas; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin; Young Adult | 2009 |
Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes.
Topics: Adamantane; Adult; Aged; Algorithms; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Topics: Adamantane; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Metformin; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Treatment Outcome; Young Adult | 2009 |
Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Edema; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Treatment Outcome; Vildagliptin; Weight Gain; Young Adult | 2009 |
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
Topics: Adamantane; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Postprandial Period; Treatment Outcome | 2009 |
Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Thiazolidinediones; Vildagliptin; Weight Gain; Young Adult | 2009 |
Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Topics: Adamantane; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemic Agents; Metformin; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2010 |
A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Young Adult | 2010 |
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
Topics: Adamantane; Adolescent; Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin; Weight Gain; Young Adult | 2010 |
Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin.
Topics: Adamantane; Administration, Oral; Adult; Aged; Blood Glucose; Circadian Rhythm; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Treatment Failure; Treatment Outcome | 2010 |
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2010 |
Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects.
Topics: Adamantane; Adolescent; Adult; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Young Adult | 2011 |
Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Young Adult | 2011 |
Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Thiazolidinediones; United States; Young Adult | 2011 |
Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes.
Topics: Adamantane; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vasodilation; Vildagliptin | 2011 |
Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.
Topics: Adamantane; Administration, Oral; Adult; Cross-Over Studies; Delayed-Action Preparations; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Food-Drug Interactions; Humans; Hypoglycemic Agents; Male; Metformin; Tablets; Therapeutic Equivalency; Young Adult | 2011 |
Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial.
Topics: Adamantane; Adult; Aged; Analysis of Variance; Asia; Asian People; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Time Factors; Treatment Outcome | 2011 |
Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden.
Topics: Adamantane; Biomarkers; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Costs; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Male; Metformin; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Sulfonylurea Compounds; Sweden; Time Factors; Treatment Outcome | 2012 |
Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.
Topics: Adamantane; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Latin America; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Postprandial Period; Treatment Outcome; United States | 2012 |
Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
Topics: Adamantane; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged | 2012 |
Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
Topics: Adamantane; Adolescent; Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Young Adult | 2012 |
Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
Topics: Adamantane; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Weight Loss | 2012 |
Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease.
Topics: Adamantane; Adiponectin; Atherosclerosis; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Humans; Hypoglycemic Agents; Inflammation; Inflammation Mediators; Interleukin-1beta; Interleukin-6; Israel; Matrix Metalloproteinase 9; Metformin; Nitriles; Platelet Function Tests; Prospective Studies; Pyrrolidines; Research Design; Thrombosis; Time Factors; Treatment Outcome; Vildagliptin | 2012 |
Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Inflammation; Interleukin-18; Interleukin-6; Male; Metformin; Middle Aged; Nitriles; Oxidative Stress; Postprandial Period; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2012 |
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?
Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrazines; Pyrrolidines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin | 2012 |
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; France; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pilot Projects; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin; Young Adult | 2012 |
Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Tolerance; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged | 2012 |
Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Asia; Australia; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; United States; Vildagliptin | 2013 |
Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study.
Topics: Adamantane; Adult; Chemokines; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Down-Regulation; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Intention to Treat Analysis; Intercellular Signaling Peptides and Proteins; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Resistin; Retinol-Binding Proteins, Plasma; Vildagliptin | 2012 |
Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus.
Topics: Adamantane; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Nitriles; Postprandial Period; Proinsulin; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2013 |
Vildagliptin more effectively achieves a composite endpoint of HbA₁c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment.
Topics: Adamantane; Aged; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin; Weight Gain | 2013 |
Bioequivalence of saxagliptin/metformin immediate release (IR) fixed-dose combination tablets and single-component saxagliptin and metformin IR tablets in healthy adult subjects.
Topics: Adamantane; Administration, Oral; Adult; Chemistry, Pharmaceutical; Cross-Over Studies; Delayed-Action Preparations; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemic Agents; Male; Metformin; New Jersey; Postprandial Period; Tablets; Therapeutic Equivalency; Young Adult | 2013 |
Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study.
Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Erythrocyte Deformability; Female; Germany; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Laser-Doppler Flowmetry; Male; Metformin; Microcirculation; Middle Aged; Nitriles; Pyrrolidines; Regional Blood Flow; Retinal Vessels; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Vildagliptin | 2013 |
RETRACTED: Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients.
Topics: Adamantane; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; GPI-Linked Proteins; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Lectins; Male; Metformin; Middle Aged; Nicotinamide Phosphoribosyltransferase; Nitriles; Pyrrolidines; Serpins; Vildagliptin | 2013 |
Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus.
Topics: Adamantane; Aged; Aged, 80 and over; Analysis of Variance; Area Under Curve; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Male; Metformin; Thiazolidinediones; Treatment Outcome | 2013 |
Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2013 |
Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.
Topics: Adamantane; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Feasibility Studies; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Nitriles; Precision Medicine; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2013 |
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemic Agents; Metformin; Risk Factors; Thiazolidinediones | 2013 |
Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring.
Topics: Adamantane; Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin; Young Adult | 2013 |
Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prospective Studies; Time Factors; Treatment Outcome | 2013 |
Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
Topics: Adamantane; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Headache; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Time Factors; Treatment Outcome; Urinary Tract Infections; Young Adult | 2013 |
Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study.
Topics: Adamantane; Age Factors; Asian People; Biomarkers; Body Mass Index; China; Clinical Protocols; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Research Design; Time Factors; Treatment Outcome; Vildagliptin | 2013 |
[A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition].
Topics: Absorptiometry, Photon; Adamantane; Blood Glucose; Body Composition; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin; Waist Circumference | 2013 |
Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2014 |
A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
Topics: Adamantane; Adult; Australia; Blood Glucose; Body Mass Index; Body Weight; Canada; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; India; Korea; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thailand; Treatment Outcome; United Kingdom | 2014 |
[Efficacy and safety of vildagliptin as a second-line therapy vs other oral antidiabetic agents in patients with type 2 diabetes: Czech results within the worldwide prospective cohort EDGE study].
Topics: Adamantane; Adult; Aged; Cohort Studies; Czech Republic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Vildagliptin; Weight Gain | 2013 |
Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glipizide; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged | 2014 |
Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.
Topics: Adamantane; Adolescent; Adult; Blood Glucose; Cyclohexanes; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Healthy Volunteers; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Liraglutide; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Nateglinide; Nitriles; Phenylalanine; Prognosis; Pyrrolidines; Somatostatin; Vildagliptin; Young Adult | 2014 |
Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients.
Topics: Adamantane; Adult; Aged; Arginine; C-Reactive Protein; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Female; Fibrinogen; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitric Oxide; Nitriles; Pyrrolidines; Vildagliptin | 2014 |
Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies.
Topics: Adamantane; Adult; Aged; Blood Glucose; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2014 |
Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
Topics: Adamantane; Adiponectin; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dietary Fats; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Male; Metformin; Middle Aged; Nitriles; Proinsulin; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha; Vildagliptin | 2014 |
Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
Topics: Adamantane; Adult; Asian People; Blood Glucose; Body Weight; China; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2014 |
Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial.
Topics: Adamantane; Adolescent; Adult; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Intention to Treat Analysis; Metformin; Middle Aged; Nitriles; Obesity; Overweight; Pyrrolidines; Research Design; Vildagliptin; Young Adult | 2014 |
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Intention to Treat Analysis; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin; Weight Gain; Weight Loss | 2014 |
Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Topics: Adamantane; Asian People; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period | 2014 |
Improved Insulin Secretion by Autologous Islet Transplantation, Compared to Oral Antidiabetic Agents, After Distal Pancreatectomy.
Topics: Adamantane; Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; HMGB1 Protein; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans Transplantation; Male; Metformin; Middle Aged; Nitriles; Pancreatectomy; Pancreatic Neoplasms; Pyrrolidines; Transplantation, Autologous; Vascular Endothelial Growth Factor A; Vildagliptin | 2015 |
Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult Chinese subjects.
Topics: Adamantane; Adolescent; Adult; China; Cohort Studies; Cross-Over Studies; Delayed-Action Preparations; Dipeptides; Healthy Volunteers; Humans; Male; Metformin; Tablets; Therapeutic Equivalency; Young Adult | 2014 |
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Topics: Adamantane; Adult; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fasting; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Metformin; Risk Factors | 2014 |
Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus.
Topics: Adamantane; Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, LDL; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2015 |
Effect of vildagliptin on hepatic steatosis.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Fatty Liver; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Triglycerides; Vildagliptin | 2015 |
Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION).
Topics: Adamantane; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Metformin; Sulfonylurea Compounds; Treatment Outcome | 2015 |
Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin.
Topics: Acarbose; Adamantane; Aged; Aged, 80 and over; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2015 |
Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2015 |
Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2015 |
Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
Topics: Acarbose; Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Monitoring, Ambulatory; Nitriles; Pyrrolidines; Vildagliptin | 2015 |
A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin; Whey Proteins | 2016 |
Bioequivalence and food effect assessment for vildagliptin/metformin fixed-dose combination tablets relative to free combination of vildagliptin and metformin in Japanese healthy subjects.
Topics: Adamantane; Adult; Area Under Curve; Cross-Over Studies; Drug Combinations; Food-Drug Interactions; Humans; Hypoglycemic Agents; Male; Metformin; Nitriles; Pyrrolidines; Tablets; Therapeutic Equivalency; Vildagliptin | 2016 |
Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Topics: Adamantane; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2016 |
[New attempt in a benefit evaluation].
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Metformin; Sulfonylurea Compounds | 2015 |
Combination of Saxagliptin and Metformin Is Effective as Initial Therapy in New-Onset Type 2 Diabetes Mellitus With Severe Hyperglycemia.
Topics: Adamantane; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Treatment Outcome | 2016 |
Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Topics: Adamantane; Aged; Combined Modality Therapy; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, Diabetic; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Down-Regulation; Drug Administration Schedule; Drug Therapy, Combination; Exercise Therapy; Feedback, Physiological; Female; Glucagon-Like Peptide 1; Humans; Male; Meals; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Vildagliptin | 2016 |
Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nitriles; Pilot Projects; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2016 |
Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
Topics: Adamantane; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2016 |
One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2016 |
Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
Topics: Adamantane; Aged; Asian People; Blood Glucose; Body Mass Index; China; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin | 2016 |
Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Risk Factors; Sulfonylurea Compounds; Treatment Outcome | 2016 |
COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
Topics: Adamantane; Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot
Topics: Adamantane; Adiposity; Adolescent; Adult; Androgens; Biomarkers; Blood Glucose; Delayed-Action Preparations; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Combinations; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Menstrual Cycle; Metformin; Pilot Projects; Polycystic Ovary Syndrome; Prediabetic State; Single-Blind Method; Time Factors; Treatment Outcome; Young Adult | 2017 |
Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study).
Topics: Acarbose; Adamantane; Adult; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Dipeptides; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Male; Metformin; Middle Aged; Treatment Outcome | 2017 |
Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients.
Topics: Adamantane; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptides; Endothelial Progenitor Cells; Endothelium, Vascular; Female; Humans; Male; Metformin; Middle Aged | 2017 |
The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study.
Topics: Adamantane; Aged; Biomarkers; C-Reactive Protein; Cardiac Rehabilitation; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation Mediators; Interleukin-1beta; Israel; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Time Factors; Treatment Outcome; Up-Regulation; Vildagliptin | 2017 |
Effects of saxagliptin on glucose homeostasis and body composition of obese patients with newly diagnosed pre-diabetes.
Topics: Adamantane; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucose Intolerance; Homeostasis; Humans; Insulin Resistance; Life Style; Male; Metformin; Middle Aged; Obesity; Postprandial Period; Prediabetic State; Treatment Outcome | 2017 |
A Double-Blinded Randomized Study Investigating a Possible Anti-Inflammatory Effect of Saxagliptin versus Placebo as Add-On Therapy in Patients with Both Type 2 Diabetes And Stable Coronary Artery Disease.
Topics: Adamantane; Aged; Anti-Inflammatory Agents; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Interleukin-10; Leukocytes, Mononuclear; Lipopolysaccharides; Male; Metformin; Middle Aged | 2017 |
The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dinoprost; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2017 |
Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial.
Topics: Adamantane; Analysis of Variance; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2018 |
The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3).
Topics: Adamantane; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin | 2017 |
Safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin and low-dose metformin.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2017 |
Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial.
Topics: Adamantane; Adult; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Insulin; Male; Metformin; Middle Aged; Placebos | 2018 |
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment.
Topics: Adamantane; Adult; Age of Onset; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Glycemic Index; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Metformin; Polycystic Ovary Syndrome; Prognosis; Prospective Studies | 2018 |
A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2
Topics: Adamantane; Adult; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Brazil; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2018 |
The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial.
Topics: Adamantane; Adult; Aged; Antigens, CD34; Arterial Pressure; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; District of Columbia; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Endothelial Progenitor Cells; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Time Factors; Treatment Outcome; Vascular Stiffness | 2018 |
Saxagliptin Upregulates Nesfatin-1 Secretion and Ameliorates Insulin Resistance and Metabolic Profiles in Type 2 Diabetes Mellitus.
Topics: Acarbose; Adamantane; Aged; Blood Glucose; Calcium-Binding Proteins; Diabetes Mellitus, Type 2; Dipeptides; DNA-Binding Proteins; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Male; Metabolome; Metformin; Middle Aged; Nerve Tissue Proteins; Nucleobindins; Up-Regulation | 2018 |
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome; Urinary Tract Infections | 2018 |
Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial.
Topics: Adamantane; Adult; Benzhydryl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Drug Monitoring; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Treatment Outcome | 2018 |
Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Reproductive Tract Infections; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2019 |
Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Sulfonylurea Compounds; Weight Gain | 2019 |
Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2019 |
Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects.
Topics: Adamantane; Adolescent; Adult; Benzhydryl Compounds; Cross-Over Studies; Delayed-Action Preparations; Dipeptides; Drug Combinations; Female; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Tablets; Therapeutic Equivalency; Young Adult | 2019 |
Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nitriles; Prospective Studies; Pyrrolidines; Quality of Life; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2018 |
Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
Topics: Adamantane; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Treatment Outcome | 2020 |
Impact of baseline characteristics on glycemic effects of add-on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus.
Topics: Acarbose; Adamantane; Aged; Blood Glucose; China; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Postprandial Period; Treatment Outcome | 2020 |
Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2020 |
Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes.
Topics: Adamantane; Adipose Tissue; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Humans; Liver; Metformin | 2020 |
A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
Topics: Adamantane; Adult; Biological Transport; Drug Interactions; Healthy Volunteers; HEK293 Cells; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Male; Metformin; Niacinamide; Octamer Transcription Factor-1; Organic Cation Transport Proteins; Protein Kinase Inhibitors; Young Adult | 2020 |
Comparison of the Efficacy, Tolerability and Side Effect Profile of Vildagliptin-Metformin with Metformin-GlibenclamideMamong Nigerian.
Topics: Adamantane; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Metformin; Nigeria; Nitriles; Prospective Studies; Pyrrolidines; Vildagliptin | 2021 |
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
Topics: Adamantane; Adipose Tissue; Adolescent; Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Magnetic Resonance Imaging; Metformin; Sulfonylurea Compounds; Treatment Outcome | 2022 |
67 other study(ies) available for adamantane and metformin
| Article | Year |
|---|---|
Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
[Vildagliptin (Galvus) and fixed combination vildagliptine-metformin (Eucreas) in the treatment of type 2 diabetes].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2009 |
Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes.
Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Combinations; Europe; Humans; Metformin; Nitriles; Pyrrolidines | 2008 |
Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.
Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2009 |
Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study.
Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Drug Tolerance; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney Function Tests; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Retrospective Studies; Safety; Thiazolidinediones; Vildagliptin | 2010 |
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Introduction.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liraglutide; Metformin; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2010 |
Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
Topics: Adamantane; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Gliclazide; Humans; Hypoglycemic Agents; Islam; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Time Factors; Vildagliptin | 2011 |
Effectiveness of adding vildagliptin to the treatment of diabetic patients nonresponsive to the combination of metformin and a sulphonylurea.
Topics: Adamantane; Administration, Oral; Adult; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Time Factors; Treatment Failure; Treatment Outcome; Vildagliptin | 2011 |
The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland.
Topics: Adamantane; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin, Isophane; Male; Metformin; Middle Aged; Models, Economic; Poland; Quality-Adjusted Life Years; Sulfonylurea Compounds | 2012 |
Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.
Topics: Adamantane; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality-Adjusted Life Years | 2012 |
Reply to: Ahren B et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13(9): 775-783 and Ahren B et al. Clinical evidence and mechanistic basis for vildagliptin's action when added to metfo
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines | 2012 |
Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Heart Diseases; Heart Rate; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Vildagliptin | 2012 |
Effects of vildagliptin/metformin therapy on patient-reported outcomes: work productivity, patient satisfaction, and resource utilization.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Combinations; Efficiency; Employment; Female; Health Care Costs; Health Services; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Nitriles; Patient Satisfaction; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin | 2013 |
Saxagliptin + metformin. Mostly disadvantages.
Topics: Adamantane; Administration, Oral; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Tablets; Treatment Outcome | 2013 |
Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fasting; Female; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Medication Adherence; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2013 |
Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glyburide; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Vildagliptin | 2013 |
Cognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes.
Topics: Adamantane; Aged; Aged, 80 and over; Cognition; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Nitriles; Prospective Studies; Pyrrolidines; Vildagliptin | 2013 |
Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study.
Topics: Adamantane; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; India; Metformin; Nitriles; Obesity; Postprandial Period; Pyrrolidines; Retrospective Studies; Treatment Outcome; Vildagliptin | 2014 |
Development of validated stability indicating assay method for simultaneous estimation of metformin hydrochloride and vildagliptin by RP-HPLC.
Topics: Adamantane; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Dipeptidyl-Peptidase IV Inhibitors; Drug Stability; Hypoglycemic Agents; Limit of Detection; Metformin; Nitriles; Pyrrolidines; Quality Control; Reproducibility of Results; Sensitivity and Specificity; Tablets; Vildagliptin | 2014 |
Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Germany; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2014 |
Hypoglycemia, its implications in clinical practice, and possible ways to prevent it.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Female; Glipizide; Humans; Hypoglycemia; Male; Metformin | 2014 |
Adding a DPP-4 inhibitor to metformin therapy may be safer than you think.
Topics: Adamantane; Diabetes Mellitus, Type 2; Female; Humans; Male; Metformin; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2014 |
Validation of different spectrophotometric methods for determination of vildagliptin and metformin in binary mixture.
Topics: Adamantane; Limit of Detection; Metformin; Nitriles; Pyrrolidines; Reference Standards; Spectrophotometry; Tablets; Vildagliptin | 2014 |
Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
Topics: Adamantane; Computer Simulation; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Economic; Nitriles; Portugal; Prospective Studies; Pyrrolidines; Quality-Adjusted Life Years; Risk Factors; Sulfonylurea Compounds; Vildagliptin | 2014 |
Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Nitriles; Pyrrolidines; Retrospective Studies; Vildagliptin | 2014 |
Simultaneous determination of metformin and vildagliptin in human plasma by a HILIC-MS/MS method.
Topics: Adamantane; Adult; Chromatography, Liquid; Drug Stability; Female; Humans; Hydrophobic and Hydrophilic Interactions; Limit of Detection; Linear Models; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Reproducibility of Results; Tandem Mass Spectrometry; Vildagliptin | 2014 |
Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats.
Topics: Adamantane; Animals; Arrhythmias, Cardiac; Calcium; Cardiotonic Agents; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Heart Rate; Insulin Resistance; Intracellular Space; Male; Metformin; Mitochondria; Myocardial Ischemia; Myocardial Reperfusion Injury; Nitriles; Obesity; Pyrrolidines; Rats; Rats, Wistar; Ventricular Dysfunction, Left; Vildagliptin | 2014 |
Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2014 |
Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study.
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin | 2015 |
Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study.
Topics: Adamantane; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Monitoring; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Turkey; Vildagliptin | 2015 |
Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes?
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Female; Glucosides; Humans; Male; Metformin | 2015 |
Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction.
Topics: Adamantane; Angiotensin-Converting Enzyme Inhibitors; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Enalapril; Fibrosis; Heart Rate; Hypoglycemic Agents; Male; Metformin; Myocardial Infarction; Myocardium; Nitriles; Oxidative Stress; Pyrrolidines; Rats, Wistar; Recovery of Function; Signal Transduction; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling; Vildagliptin | 2015 |
Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Asia; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Young Adult | 2016 |
Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
Topics: Adamantane; Body Mass Index; Cardiovascular Diseases; China; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Female; Hospital Costs; Humans; Hypoglycemia; Hypoglycemic Agents; Insurance Claim Review; Kidney Diseases; Male; Metformin; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Sulfonylurea Compounds | 2015 |
Regulation of Pancreatic β Cell Mass by Cross-Interaction between CCAAT Enhancer Binding Protein β Induced by Endoplasmic Reticulum Stress and AMP-Activated Protein Kinase Activity.
Topics: Adamantane; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; CCAAT-Enhancer-Binding Protein-beta; Cell Line; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; Gene Expression Regulation; Glucose Tolerance Test; Hypoglycemic Agents; Insulin-Secreting Cells; Islets of Langerhans; Metformin; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nitriles; Phosphorylation; Pyrrolidines; Ribonucleotides; Vildagliptin | 2015 |
Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus.
Topics: Adamantane; Adult; Apelin; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Time Factors; Treatment Outcome; Up-Regulation; Vildagliptin | 2015 |
Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Blood Glucose; China; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Young Adult | 2016 |
Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction.
Topics: Adamantane; Animals; Cardiotonic Agents; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enalapril; Heart Rate; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Myocardial Infarction; Nitriles; Oxidative Stress; Pyrrolidines; Rats; Rats, Wistar; Ventricular Remodeling; Vildagliptin | 2016 |
Population pharmacokinetic modeling and noncompartmental analysis demonstrated bioequivalence between metformin component of metformin/vildagliptin fixed-dose combination products and metformin immediate-release tablet sourced from various countries.
Topics: Adamantane; Adolescent; Adult; Drug Combinations; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Biological; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Retrospective Studies; Tablets; Therapeutic Equivalency; Vildagliptin; Young Adult | 2016 |
Urinary metabolomic profiling in mice with diet-induced obesity and type 2 diabetes mellitus after treatment with metformin, vildagliptin and their combination.
Topics: Adamantane; Animals; beta-Alanine; Diabetes Mellitus, Type 2; Diet; Glucose Tolerance Test; Hypoglycemic Agents; Male; Metabolomics; Metformin; Mice; Mice, Inbred C57BL; Nitriles; Obesity; Pyridones; Pyrrolidines; Vildagliptin | 2016 |
Low-carbohydrate diet combined with SGLT2 inhibitor for refractory hyperglycemia caused by insulin antibodies.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Restricted; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin Antibodies; Insulin Resistance; Male; Metformin; Nitriles; Pyrrolidines; Sodium-Glucose Transporter 2 Inhibitors; Vildagliptin | 2016 |
Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats.
Topics: Adamantane; Animals; Cardiotonic Agents; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Estrogens; Female; Heart Rate; Hypoglycemic Agents; Insulin Resistance; Menopause, Premature; Metformin; Mitochondria, Heart; Nitriles; Obesity; Ovariectomy; Oxidative Stress; Pyrrolidines; Rats; Rats, Wistar; Vildagliptin | 2016 |
Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy.
Topics: Adamantane; Adult; Age Factors; Aged; Asia, Eastern; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Latin America; Male; Metformin; Middle Aged; Middle East; Nitriles; Pyrrolidines; Sex Factors; Treatment Outcome; Vildagliptin | 2016 |
A case of bullous pemphigoid ınduced by vildagliptin.
Topics: Adamantane; Administration, Cutaneous; Clobetasol; Complement C3; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Eruptions; Female; Fluorescent Antibody Technique; Gliclazide; Glucocorticoids; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Nitriles; Pemphigoid, Bullous; Pyrrolidines; Skin; Vildagliptin; Withholding Treatment | 2017 |
LC-MS/MS analysis of metformin, saxagliptin and 5-hydroxy saxagliptin in human plasma and its pharmacokinetic study with a fixed-dose formulation in healthy Indian subjects.
Topics: Adamantane; Chromatography, Liquid; Dipeptides; Humans; Metformin; Reproducibility of Results; Solid Phase Extraction; Tandem Mass Spectrometry | 2017 |
The effect of vildagliptin relative to sulfonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan in the Middle East: the VIRTUE study.
Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemic Agents; Islam; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2017 |
Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies.
Topics: Adamantane; Adult; Aged; Asian People; Blood Glucose; China; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Ethnicity; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Insulin; Japan; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Racial Groups; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin; White People | 2017 |
Effects of Vildagliptin and Metformin on Blood Pressure and Heart Rate Responses to Small Intestinal Glucose in Type 2 Diabetes.
Topics: Adamantane; Aged; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucose; Heart Rate; Humans; Hypoglycemic Agents; Intestine, Small; Male; Metformin; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin | 2017 |
Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study.
Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Monitoring; Drug Therapy, Combination; Egypt; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin | 2017 |
Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Retrospective Studies; Treatment Outcome; Vildagliptin | 2018 |
Long-term Saxagliptin Treatment Improves Endothelial Function but not Pulse Wave Velocity and Intima-Media Thickness in Type 2 Diabetic Patients.
Topics: Adamantane; Biomarkers; Blood Glucose; Carotid Arteries; Carotid Intima-Media Thickness; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Predictive Value of Tests; Prospective Studies; Pulse Wave Analysis; Recovery of Function; Time Factors; Treatment Outcome; Vascular Stiffness | 2017 |
Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study. Curr
Topics: Adamantane; Egypt; Humans; Metformin; Non-alcoholic Fatty Liver Disease; Uric Acid; Vildagliptin | 2017 |
Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients.
Topics: Adamantane; Adipose Tissue; Adult; Aged; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Vildagliptin | 2017 |
Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin.
Topics: Adamantane; Aging; Animals; Biomarkers; Body Weight; Brain; Dementia; Dipeptides; Galactose; Glycated Hemoglobin; Hypoglycemic Agents; Insulin Resistance; Locomotion; Male; Metformin; Nerve Tissue Proteins; Oxidative Stress; Rats; Rats, Wistar; Reaction Time | 2017 |
Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study).
Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Chi-Square Distribution; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Logistic Models; Male; Metformin; Middle Aged; Multivariate Analysis; Nitriles; Pyrrolidines; Republic of Korea; Retrospective Studies; Time Factors; Treatment Outcome; Vildagliptin | 2017 |
Dipeptidyl Peptidase-4 Inhibitors and Heart Failure Exacerbation in the Veteran Population: An Observational Study.
Topics: Adamantane; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Retrospective Studies; Veterans | 2018 |
Quantitative determination of metformin, saxagliptin and 5-hydroxy saxagliptin simultaneously by hydrophilic interaction liquid chromatography - electrospray ionization mass spectrometry and its application to a bioequivalence study with a single-pill com
Topics: Adamantane; Chromatography, Liquid; Dipeptides; Drug Combinations; Humans; Hydrophobic and Hydrophilic Interactions; Linear Models; Metformin; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Therapeutic Equivalency | 2018 |
Optimization of a single HPLC-PDA method for quantifying Metformin, Gliclazide, Pioglitazone, Dapagliflozin, Empagliflozin, Saxagliptin, Linagliptin and Teneligliptin using central composite design.
Topics: Adamantane; Benzhydryl Compounds; Chromatography, High Pressure Liquid; Dipeptides; Dose-Response Relationship, Drug; Gliclazide; Glucosides; Linagliptin; Metformin; Molecular Structure; Pioglitazone; Pyrazoles; Software; Structure-Activity Relationship; Thiazolidines | 2019 |
Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus.
Topics: Adamantane; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Glucosides; Humans; Metformin; Prospective Studies; Randomized Controlled Trials as Topic | 2021 |
Vitamin D3 potentiates the nephroprotective effects of vildagliptin-metformin combination in a rat model of metabolic syndrome.
Topics: Adamantane; Animals; Cholecalciferol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Vildagliptin | 2022 |
Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China.
Topics: Adamantane; China; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Humans; Linagliptin; Metformin; Middle Aged; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil; Vildagliptin | 2021 |
Stability-indicating HPLC method development and validation for simultaneous estimation of metformin, dapagliflozin, and saxagliptin in bulk drug and pharmaceutical dosage form.
Topics: Adamantane; Benzhydryl Compounds; Chromatography, High Pressure Liquid; Dipeptides; Drug Stability; Glucosides; Metformin; Tablets | 2022 |
Variation in open access vildagliptin use in Waikato patients with type 2 diabetes.
Topics: Access to Information; Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; New Zealand; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2022 |